Brain Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been previously diagnosed (confirmed by tissue testing) with medulloblastoma or ependymoma that has come back, and are experiencing their first or second relapse.
• People whose tumour can be reached and removed or sampled through surgery, with enough tissue expected to meet the study's minimum requirements.
• People who have already received at least one prior treatment at the time of their original diagnosis.
• People who have fully recovered from the side effects of any prior chemotherapy, immunotherapy, or radiation before joining the study.
• People whose last chemotherapy or biological treatment was given at least 7 days before registering for the trial (at least 21 days for monoclonal antibody treatments or bevacizumab).
• People whose last dose of radiation to the main tumour area or to the spine/whole body was at least 12 weeks before registering, or at least 14 days for smaller, localised palliative radiation.
• People aged 12 months to 39 years old.
• People who have a reasonable level of physical functioning, as measured by standard medical scoring tools (Karnofsky score of 50 or above for those over 16 years old, or Lansky score of 50 or above for those 16 and under) — people who use a wheelchair but are not bed-bound may still meet this requirement.
• People taking a steroid medication such as dexamethasone, provided the dose has been stable or reducing for at least one week before registering.
• People whose blood counts, kidney function, and liver function fall within the acceptable ranges required by the trial, based on tests done within 7 days before registering (confirm specific values with trial site).
• People with a seizure disorder may be eligible if their seizures are well controlled, though certain seizure medications may affect eligibility depending on how they interact with the study drug (confirm with trial site).
• People who are willing and able (or whose parent or legal guardian is willing and able) to sign a written consent form.
• People who agree to use adequate birth control (hormonal, barrier method, or abstinence) during the study and for 4 months after treatment ends, if there is any possibility of pregnancy.
• People who are willing to also enrol in a related study looking at thinking, quality of life, and the broader effects of treatment (PNOC COMP), if that study is available at the enrolling site.

Who may not be able to join:

• People who have received chemotherapy or radiation within 3 weeks before joining (or 6 weeks for certain specific chemotherapy drugs called nitrosoureas or mitomycin C), or who have not recovered from side effects of treatments given more than 4 weeks earlier.
• People who are currently taking part in another clinical trial involving an investigational treatment.
• People who are currently receiving any other anti-cancer treatment (note: steroids are not counted as anti-cancer therapy for this purpose).
• People who have an uncontrolled or active infection or other serious uncontrolled illness at the time of enrolment.
• People who are pregnant or breastfeeding — a negative pregnancy test is required before starting treatment.
• People who receive any tumour-directed therapy after joining the trial, other than the surgical removal or biopsy that is part of the study.
• People whose last dose of a biological or small-molecule treatment was less than 7 days before enrolment, or who have not yet passed the period during which known side effects of that treatment can occur.

Important: Always verify eligibility with the trial site directly before applying.